The bnp and ntprobnp market size has grown rapidly in recent years. It will grow from $2.26 billion in 2025 to $2.54 billion in 2026 at a compound annual growth rate (CAGR) of 12.2%. The growth in the historic period can be attributed to rising prevalence of cardiovascular diseases, increased clinical adoption of bnp testing, expansion of hospital diagnostic infrastructure, growing awareness of early heart failure detection, availability of laboratory immunoassay technologies.
The bnp and ntprobnp market size is expected to see rapid growth in the next few years. It will grow to $4.03 billion in 2030 at a compound annual growth rate (CAGR) of 12.3%. The growth in the forecast period can be attributed to increasing demand for rapid cardiac diagnostics, expansion of point-of-care testing adoption, growing elderly population base, rising integration of ai-assisted diagnostic interpretation, increasing focus on preventive cardiology care. Major trends in the forecast period include increasing adoption of high-sensitivity cardiac biomarker assays, rising use of point-of-care bnp testing devices, growing integration of automated laboratory diagnostics, expansion of early heart failure screening programs, enhanced focus on rapid turnaround diagnostic testing.
The increasing geriatric population is anticipated to drive the growth of the BNP and NT-proBNP market in the coming years. The geriatric population refers to older adults, generally defined as individuals aged 65 or above. BNP and NT-proBNP act as essential biomarkers in this population, assisting in the diagnosis and management of heart failure by providing key insights into cardiac function and supporting the implementation of suitable treatment strategies for elderly individuals. For example, in October 2025, according to the World Health Organization, a US-based specialized health agency, globally, 1 in 6 people will be 60 or older by 2030, with the elderly population expected to reach 2.1 billion by 2050. Consequently, the growing geriatric population is fueling the expansion of the BNP and NT-proBNP market.
Key players in the BNP and NT-proBNP market are increasingly focusing on launching rapid screening bioassays to strengthen their competitive position. Rapid screening bioassays are biological tests that efficiently measure the presence, concentration, or activity of a substance by assessing its effects on living cells or organisms, allowing quick and reliable detection or categorization of specific conditions. For instance, in October 2023, Mindray Medical International Limited, a China-based medical device company, introduced two new assays for the diagnosis and management of cardiovascular diseases (CVDs). These assays are high-sensitivity troponin I (hs-cTnI) and N-terminal pro-B-type natriuretic peptide (NT-proBNP). By adding these assays to its comprehensive portfolio of cardiac biomarkers, Mindray has strengthened its capability to screen, stratify risk, diagnose quickly, and monitor therapy for CVDs. Mindray partnered with HyTest, a pioneer in cardiac biomarkers, to integrate HyTest's research and antibodies into Mindray's immunoassay platforms.
In July 2024, Roche Holding AG, a Switzerland-based pharmaceutical and diagnostics company, acquired LumiraDx Limited for an undisclosed sum. This acquisition is intended to expand Roche's diagnostics portfolio by incorporating innovative point-of-care technology that facilitates rapid testing for BNP and NT-proBNP. LumiraDx Limited, a UK-based diagnostics company, is known for its pioneering rapid test for NT-proBNP.
Major companies operating in the bnp and ntprobnp market are Abbott Laboratories, Gentian Diagnostics ASA, Siemens AG, PerkinElmer Inc., Biomerieux SA, Quidel Corporation, Bio-Rad Laboratories Inc., F Hoffman La Roche Ltd., CTK Biotech Inc., RayBiotech Life Inc., BHR Pharmaceuticals Ltd., Getein Biotech Inc., VACURE Biotechnology Co. Ltd., Bio-Techne Co., Xiamen Biotime Biotechnology Co. Ltd., Scripps Laboratories Inc., Danaher Corporation, Beckman Coulter Inc., Thermo Fisher Scientific Inc., Randox Laboratories Ltd., LSI Medience Corporation, Shionogi & Co. Ltd., Radiometer Medical ApS, Ortho Clinical Diagnostics, Tosoh Corporation, Aidian Oy, Shenzhen Mindray Bio-Medical Electronics Co. Ltd., Becton Dickinson and Company, Acon Laboratories Inc., Response Biomedical Corp., Nanomix Inc., Cepheid Inc., Alere Inc.
Asia-Pacific was the largest region in the BNP and NTproBNP market in 2025.North America is expected to be the fastest-growing region in the global BNP and NTproBNP market report during the forecast period. The regions covered in the bnp and ntprobnp market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the bnp and ntprobnp market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the bnp and ntprobnp market by increasing costs of imported immunoassay reagents, diagnostic analyzers, electronic components, and point-of-care testing devices used in hospital and laboratory settings. Diagnostic laboratories and healthcare providers in North America and Europe are most affected due to reliance on globally sourced assay kits and analyzers, while Asia-Pacific faces cost pressure on manufacturing and export of diagnostic consumables. These tariffs are increasing test pricing and procurement costs for healthcare systems. However, they are also encouraging localized production of diagnostic kits, regional supply chain diversification, and investment in domestic diagnostic manufacturing capabilities.
The bnp and ntprobnp market research report is one of a series of new reports that provides bnp and ntprobnp market statistics, including bnp and ntprobnp industry global market size, regional shares, competitors with a bnp and ntprobnp market share, detailed bnp and ntprobnp market segments, market trends and opportunities, and any further data you may need to thrive in the bnp and ntprobnp industry. This bnp and ntprobnp market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
A BNP (B-type natriuretic peptide) and NT-proBNP (N-terminal pro-brain natriuretic peptide) test measures the levels of BNP or its prohormone NT-proBNP in the bloodstream, helping to detect heart failure and other cardiac conditions. BNP and NT-proBNP are natriuretic peptides that play a key role in regulating blood circulation. Elevated levels of BNP or NT-proBNP indicate the presence of heart disease, reflecting abnormalities in the heart’s ability to pump blood.
The primary types of BNP and NT-proBNP are BNP (brain natriuretic peptide) and NT-proBNP (N-terminal pro-B-type natriuretic peptide). A BNP test measures the concentration of BNP in the blood to identify heart failure and other cardiac issues. Testing can be performed at point-of-care locations or in laboratories for conditions such as myocardial infarction, congestive heart failure, acute coronary syndrome (ACS), and other heart-related disorders.
The BNP and NTproBNP market includes revenues earned by companies by providing diagnostic and heart disease detection services using BNP (B-type natriuretic peptide) or NT-proBNP (N-terminal Pro-brain Natriuretic Peptide) as biomarkers, BNP and NTproBNP assays. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The bnp and ntprobnp market size is expected to see rapid growth in the next few years. It will grow to $4.03 billion in 2030 at a compound annual growth rate (CAGR) of 12.3%. The growth in the forecast period can be attributed to increasing demand for rapid cardiac diagnostics, expansion of point-of-care testing adoption, growing elderly population base, rising integration of ai-assisted diagnostic interpretation, increasing focus on preventive cardiology care. Major trends in the forecast period include increasing adoption of high-sensitivity cardiac biomarker assays, rising use of point-of-care bnp testing devices, growing integration of automated laboratory diagnostics, expansion of early heart failure screening programs, enhanced focus on rapid turnaround diagnostic testing.
The increasing geriatric population is anticipated to drive the growth of the BNP and NT-proBNP market in the coming years. The geriatric population refers to older adults, generally defined as individuals aged 65 or above. BNP and NT-proBNP act as essential biomarkers in this population, assisting in the diagnosis and management of heart failure by providing key insights into cardiac function and supporting the implementation of suitable treatment strategies for elderly individuals. For example, in October 2025, according to the World Health Organization, a US-based specialized health agency, globally, 1 in 6 people will be 60 or older by 2030, with the elderly population expected to reach 2.1 billion by 2050. Consequently, the growing geriatric population is fueling the expansion of the BNP and NT-proBNP market.
Key players in the BNP and NT-proBNP market are increasingly focusing on launching rapid screening bioassays to strengthen their competitive position. Rapid screening bioassays are biological tests that efficiently measure the presence, concentration, or activity of a substance by assessing its effects on living cells or organisms, allowing quick and reliable detection or categorization of specific conditions. For instance, in October 2023, Mindray Medical International Limited, a China-based medical device company, introduced two new assays for the diagnosis and management of cardiovascular diseases (CVDs). These assays are high-sensitivity troponin I (hs-cTnI) and N-terminal pro-B-type natriuretic peptide (NT-proBNP). By adding these assays to its comprehensive portfolio of cardiac biomarkers, Mindray has strengthened its capability to screen, stratify risk, diagnose quickly, and monitor therapy for CVDs. Mindray partnered with HyTest, a pioneer in cardiac biomarkers, to integrate HyTest's research and antibodies into Mindray's immunoassay platforms.
In July 2024, Roche Holding AG, a Switzerland-based pharmaceutical and diagnostics company, acquired LumiraDx Limited for an undisclosed sum. This acquisition is intended to expand Roche's diagnostics portfolio by incorporating innovative point-of-care technology that facilitates rapid testing for BNP and NT-proBNP. LumiraDx Limited, a UK-based diagnostics company, is known for its pioneering rapid test for NT-proBNP.
Major companies operating in the bnp and ntprobnp market are Abbott Laboratories, Gentian Diagnostics ASA, Siemens AG, PerkinElmer Inc., Biomerieux SA, Quidel Corporation, Bio-Rad Laboratories Inc., F Hoffman La Roche Ltd., CTK Biotech Inc., RayBiotech Life Inc., BHR Pharmaceuticals Ltd., Getein Biotech Inc., VACURE Biotechnology Co. Ltd., Bio-Techne Co., Xiamen Biotime Biotechnology Co. Ltd., Scripps Laboratories Inc., Danaher Corporation, Beckman Coulter Inc., Thermo Fisher Scientific Inc., Randox Laboratories Ltd., LSI Medience Corporation, Shionogi & Co. Ltd., Radiometer Medical ApS, Ortho Clinical Diagnostics, Tosoh Corporation, Aidian Oy, Shenzhen Mindray Bio-Medical Electronics Co. Ltd., Becton Dickinson and Company, Acon Laboratories Inc., Response Biomedical Corp., Nanomix Inc., Cepheid Inc., Alere Inc.
Asia-Pacific was the largest region in the BNP and NTproBNP market in 2025.North America is expected to be the fastest-growing region in the global BNP and NTproBNP market report during the forecast period. The regions covered in the bnp and ntprobnp market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the bnp and ntprobnp market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the bnp and ntprobnp market by increasing costs of imported immunoassay reagents, diagnostic analyzers, electronic components, and point-of-care testing devices used in hospital and laboratory settings. Diagnostic laboratories and healthcare providers in North America and Europe are most affected due to reliance on globally sourced assay kits and analyzers, while Asia-Pacific faces cost pressure on manufacturing and export of diagnostic consumables. These tariffs are increasing test pricing and procurement costs for healthcare systems. However, they are also encouraging localized production of diagnostic kits, regional supply chain diversification, and investment in domestic diagnostic manufacturing capabilities.
The bnp and ntprobnp market research report is one of a series of new reports that provides bnp and ntprobnp market statistics, including bnp and ntprobnp industry global market size, regional shares, competitors with a bnp and ntprobnp market share, detailed bnp and ntprobnp market segments, market trends and opportunities, and any further data you may need to thrive in the bnp and ntprobnp industry. This bnp and ntprobnp market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
A BNP (B-type natriuretic peptide) and NT-proBNP (N-terminal pro-brain natriuretic peptide) test measures the levels of BNP or its prohormone NT-proBNP in the bloodstream, helping to detect heart failure and other cardiac conditions. BNP and NT-proBNP are natriuretic peptides that play a key role in regulating blood circulation. Elevated levels of BNP or NT-proBNP indicate the presence of heart disease, reflecting abnormalities in the heart’s ability to pump blood.
The primary types of BNP and NT-proBNP are BNP (brain natriuretic peptide) and NT-proBNP (N-terminal pro-B-type natriuretic peptide). A BNP test measures the concentration of BNP in the blood to identify heart failure and other cardiac issues. Testing can be performed at point-of-care locations or in laboratories for conditions such as myocardial infarction, congestive heart failure, acute coronary syndrome (ACS), and other heart-related disorders.
The BNP and NTproBNP market includes revenues earned by companies by providing diagnostic and heart disease detection services using BNP (B-type natriuretic peptide) or NT-proBNP (N-terminal Pro-brain Natriuretic Peptide) as biomarkers, BNP and NTproBNP assays. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. BNP and NTproBNP Market Characteristics
3. BNP and NTproBNP Market Supply Chain Analysis
4. Global BNP and NTproBNP Market Trends and Strategies
5. BNP and NTproBNP Market Analysis of End Use Industries
7. Global BNP and NTproBNP Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global BNP and NTproBNP Total Addressable Market (TAM) Analysis for the Market
9. BNP and NTproBNP Market Segmentation
10. BNP and NTproBNP Market Regional and Country Analysis
11. Asia-Pacific BNP and NTproBNP Market
12. China BNP and NTproBNP Market
13. India BNP and NTproBNP Market
14. Japan BNP and NTproBNP Market
15. Australia BNP and NTproBNP Market
16. Indonesia BNP and NTproBNP Market
17. South Korea BNP and NTproBNP Market
18. Taiwan BNP and NTproBNP Market
19. South East Asia BNP and NTproBNP Market
20. Western Europe BNP and NTproBNP Market
21. UK BNP and NTproBNP Market
22. Germany BNP and NTproBNP Market
23. France BNP and NTproBNP Market
24. Italy BNP and NTproBNP Market
25. Spain BNP and NTproBNP Market
26. Eastern Europe BNP and NTproBNP Market
27. Russia BNP and NTproBNP Market
28. North America BNP and NTproBNP Market
29. USA BNP and NTproBNP Market
30. Canada BNP and NTproBNP Market
31. South America BNP and NTproBNP Market
32. Brazil BNP and NTproBNP Market
33. Middle East BNP and NTproBNP Market
34. Africa BNP and NTproBNP Market
36. BNP and NTproBNP Market Competitive Landscape and Company Profiles
37. BNP and NTproBNP Market Other Major and Innovative Companies
40. BNP and NTproBNP Market High Potential Countries, Segments and Strategies
41. Appendix
Executive Summary
BNP And NTproBNP Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses bnp and ntprobnp market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for bnp and ntprobnp? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The bnp and ntprobnp market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Type: BNP (Brain Natriuretic Peptide); NT-proBNP (N-terminal Pro-B-Type Natriuretic Peptide)2) By Location Of Testing: Point Of Care Testing; Laboratory Testing
3) By Application: Myocardial Infarction; Congestive Heart Failure; Acute Coronary Syndrome (ACS); Other Applications
Subsegments:
1) By BNP (Brain Natriuretic Peptide): BNP Testing Kits; Point-Of-Care BNP Testing Devices; Laboratory BNP Assays2) By NT-ProBNP (N-Terminal Pro-B-Type Natriuretic Peptide): NT-ProBNP Testing Kits; Point-Of-Care NT-proBNP Testing Devices; Laboratory NT-ProBNP Assays
Companies Mentioned: Abbott Laboratories; Gentian Diagnostics ASA; Siemens AG; PerkinElmer Inc.; Biomerieux SA; Quidel Corporation; Bio-Rad Laboratories Inc.; F Hoffman La Roche Ltd.; CTK Biotech Inc.; RayBiotech Life Inc.; BHR Pharmaceuticals Ltd.; Getein Biotech Inc.; VACURE Biotechnology Co. Ltd.; Bio-Techne Co.; Xiamen Biotime Biotechnology Co. Ltd.; Scripps Laboratories Inc.; Danaher Corporation; Beckman Coulter Inc.; Thermo Fisher Scientific Inc.; Randox Laboratories Ltd.; LSI Medience Corporation; Shionogi & Co. Ltd.; Radiometer Medical ApS; Ortho Clinical Diagnostics; Tosoh Corporation; Aidian Oy; Shenzhen Mindray Bio-Medical Electronics Co. Ltd.; Becton Dickinson and Company; Acon Laboratories Inc.; Response Biomedical Corp.; Nanomix Inc.; Cepheid Inc.; Alere Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this BNP and NTproBNP market report include:- Abbott Laboratories
- Gentian Diagnostics ASA
- Siemens AG
- PerkinElmer Inc.
- Biomerieux SA
- Quidel Corporation
- Bio-Rad Laboratories Inc.
- F Hoffman La Roche Ltd.
- CTK Biotech Inc.
- RayBiotech Life Inc.
- BHR Pharmaceuticals Ltd.
- Getein Biotech Inc.
- VACURE Biotechnology Co. Ltd.
- Bio-Techne Co.
- Xiamen Biotime Biotechnology Co. Ltd.
- Scripps Laboratories Inc.
- Danaher Corporation
- Beckman Coulter Inc.
- Thermo Fisher Scientific Inc.
- Randox Laboratories Ltd.
- LSI Medience Corporation
- Shionogi & Co. Ltd.
- Radiometer Medical ApS
- Ortho Clinical Diagnostics
- Tosoh Corporation
- Aidian Oy
- Shenzhen Mindray Bio-Medical Electronics Co. Ltd.
- Becton Dickinson and Company
- Acon Laboratories Inc.
- Response Biomedical Corp.
- Nanomix Inc.
- Cepheid Inc.
- Alere Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 2.54 Billion |
| Forecasted Market Value ( USD | $ 4.03 Billion |
| Compound Annual Growth Rate | 12.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 34 |
